Lynx1 Capital Management LP Pharvaris N.V. Transaction History

Lynx1 Capital Management LP

  • $279 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023
SELL
$7.82 - $16.0 $39,100 - $80,000
-5,000 Reduced 19.07%
21,225 $321,000
Q1 2023

May 15, 2023
BUY
$6.34 - $12.27 $5,706 - $11,043
900 Added 3.55%
26,225 $211,000
Q4 2022

Feb 14, 2023
BUY
$1.98 - $11.46 $50,143 - $290,224
25,325 New
25,325 $284,000

Others Institutions Holding PHVS

# of Institutions
51
Shares Held
39.6M
Call Options Held
0
Put Options Held
0
View Full List

About Pharvaris N.V.

PHVS Quotes by TradingView
  • Ticker PHVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,766,000
  • Market Cap $625M
  • Description
  • Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...
More about PHVS
Track This Portfolio

Track Lynx1 Capital Management LP Portfolio

Follow Lynx1 Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lynx1 Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Lynx1 Capital Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email